Cargando…

A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies

Patients with hematological malignancies have an increased risk of serious outcomes following COVID-19 infection, suggesting broader protection is needed beyond vaccination. Monoclonal antibodies such as sotrovimab, casirivimab–imdevimab, and bamlanivimab have provided valuable options for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Owen, Carolyn, Robinson, Sue, Christofides, Anna, Sehn, Laurie H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222187/ https://www.ncbi.nlm.nih.gov/pubmed/35735424 http://dx.doi.org/10.3390/curroncol29060315

Ejemplares similares

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
por: Melosky, B., et al.
Publicado: (2009)

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
por: Ho, Cheryl, et al.
Publicado: (2022)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Antiphospholipid Antibodies and Lipids in Hematological Malignancies
por: Barreno-Rocha, Sonia Guadalupe, et al.
Publicado: (2022)

A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia
por: Kaedbey, Rayan, et al.
Publicado: (2022)

Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
por: De Benedictis, Paola, et al.
Publicado: (2016)

Monoclonal Antibodies for the Prevention and Treatment of COVID-19 Disease in Patients With Hematological Malignancies: Two Case Reports and a Literature Review
por: Klank, David, et al.
Publicado: (2021)

Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
por: Mahimainathan, Lenin, et al.
Publicado: (2020)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Trends in Malignant Glioma Monoclonal Antibody Therapy
por: Chekhonin, Ivan, et al.
Publicado: (2015)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans
por: Müller, Thomas, et al.
Publicado: (2009)

Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits
por: Morel, Antoine, et al.
Publicado: (2021)

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies
por: Han, Yizhao, et al.
Publicado: (2020)

Bispecific Antibodies in Hematological Malignancies: A Scoping Review
por: Omer, Mohamed H., et al.
Publicado: (2023)

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
por: Mosch, Romy, et al.
Publicado: (2022)

Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis
por: Popping, Stephanie, et al.
Publicado: (2023)

Pre-transplant Rehabilitation to Decrease the Post-transplant Length of Stay for Hematological Malignancy Patients Undergoing Allo-HSCT
por: Matsugaki, Ryutaro, et al.
Publicado: (2021)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

Correction: Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans
por: Müller, Thomas, et al.
Publicado: (2009)

SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies
por: Chao, Tzu-Yuan, et al.
Publicado: (2017)

Feasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities
por: Mena Lora, Alfredo J., et al.
Publicado: (2023)

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

Quantitation of exposure to benzo[a]pyrene with monoclonal antibodies.
por: Santella, R M, et al.
Publicado: (1985)

Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax
por: Tang, Qi, et al.
Publicado: (2018)

Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
por: Adams, Rebecca, et al.
Publicado: (2022)

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
por: Marchesi, Francesco, et al.
Publicado: (2023)

Cognitive Vulnerability to Depression in Canadian and Chinese Adolescents
por: Auerbach, Randy P., et al.
Publicado: (2009)

Vulnerability of Canadian aquatic ecosystems to nuclear accidents
por: Brinkmann, Lars, et al.
Publicado: (2017)

Massage for Symptom Management in Adult Inpatients With Hematologic Malignancies
por: Kuon, Carla, et al.
Publicado: (2019)

Malignant mesothelioma: Canadian perspective and research directions
por: Lee, C.W., et al.
Publicado: (2008)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
por: Kyriakidis, Ioannis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lmdjfb9pp28id8ilq2b7k7bif3